Carisma Therapeutics (CARM) Stock Price, News & Analysis

Company Overview

Carisma Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.

The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors. In parallel, Carisma is advancing CT-381, an engineered myeloid cell therapy designed to modulate inflammatory and autoimmune conditions. Preclinical data have demonstrated robust antigen-dependent activation, tumor penetration and anti-tumor efficacy in multiple models, supporting the progression of these programs toward their first clinical studies.

Carisma’s interdisciplinary team combines expertise in myeloid biology, genetic engineering and translational medicine. The company partners with leading academic institutions and specialized contract development and manufacturing organizations to establish scalable, GMP-compliant processes for its cell therapies. By uniting macrophage biology with CAR engineering, Carisma Therapeutics seeks to create a novel class of treatments with broad applications across oncology and immune-mediated diseases.

Key Stats

• Today's Range: $0.0081 to $0.01
• 50-Day Range: $0.00 to $0.03
• 52-Week Range: $0.00 to $0.56
• Volume: 17,643 shs
• Average Volume: 82,568 shs
• Market Capitalization: $338.94 thousand
• P/E Ratio: 0.01
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Moderate Buy

Carisma Therapeutics Stock Analysis - MarketRank™

Carisma Therapeutics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Carisma Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Carisma Therapeutics has a consensus price target of $1.00, representing about 12,245.7% upside from its current price of $0.01.

Amount of Analyst Coverage

Carisma Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.32) to ($1.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Carisma Therapeutics is 0.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.06.

Price to Earnings Ratio vs. Sector

The P/E ratio of Carisma Therapeutics is 0.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.43.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CARM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Carisma Therapeutics does not currently pay a dividend.

Dividend Growth

Carisma Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for CARM on MarketBeat in the last 30 days.

MarketBeat Follows

6 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.90% of the stock of Carisma Therapeutics is held by insiders.

Percentage Held by Institutions

44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CARM
• CIK: 1485003
• Web: N/A
• Phone: 617-444-8550
• Fax: 617-858-0911
• Employees: 20
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Carisma Therapeutics: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: +12,245.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.73
• Trailing P/E Ratio: 0.01
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.48 million
• Net Margins: -254.28%
• Pretax Margin: -458.60%
• Return on Equity: N/A
• Return on Assets: -192.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.48
• Quick Ratio: 0.48

Sales & Book Value

• Annual Sales: $10.77 million
• Price / Sales: 0.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.67) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 41,845,000
• Free Float: 38,905,000
• Market Cap: $338.94 thousand
• Optionable: No Data
• Beta: 0.80